CorPath GRX is a second generation robotic-assisted system built on the foundation of the CorPath 200’s clinical success with over 5,000 cases across more than 50 cardiovascular programs worldwide.
When using the CorPath System, studies have shown:*
The CORA-PCI Trial demonstrated 99.1% clinical success in complex cases along with comparable procedure times to manual PCI.1
A recent study demonstrated that accurate measurement of coronary anatomy, using CorPath, reduced the use of unnecessary additional stents by 8.3%.2
A single center retrospective study published in the Journal of Invasive Cardiology demonstrated a 17% reduction in radiation dose to the patient compared to manual PCI.3
The PRECISE trial demonstrated a 95% reduction in radiation exposure to the primary operator.4
1. Mahmud E, et al. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the Complex Robotically Assisted Percutaneous Coronary Intervention (CORA-PCI) Trial. Presented at SCAI 2016; Orlando, FL.
2. Campbell PT, et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification for stent savings. Cardiovasc Revasc Med. 2015;piii:S1553-8389.
3. Smilowitz N, et al. Robotic-Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol, 2014;26(7):318-321.
4. Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J American College of Cardiol, 2013, Vol 61, No. 15: 1596-1600.
* Includes studies conducted using CorPath 200
** Compared to the CorPath 200 System
